GLP-1 diabetes meds may curb worsening anxiety and depression, study finds

A large Swedish study of about 95,000 people with depression or anxiety who were taking diabetes medications found that GLP-1 receptor agonists—especially semaglutide and liraglutide—were associated with a lower risk of worsening mental health outcomes such as hospitalizations, sick leave, self-harm, or death, while other GLP-1 drugs did not show the same benefit; experts caution about drawing causality from observational data. A separate Danish study linked first-trimester exposure to semaglutide or liraglutide for diabetes with a higher risk of preterm birth.